Journal
ADVANCED SCIENCE
Volume 10, Issue 19, Pages -Publisher
WILEY
DOI: 10.1002/advs.202207512
Keywords
CRISPR; Cas9; gene editing; in vivo delivery; nanomedicine
Ask authors/readers for more resources
CRISPR and Cas9, initially discovered as an immune system in bacteria and archaea, are now widely used as biotechnological tools for genetic and nongenetic disease treatment. Clinical trials mainly adopt ex vivo strategies, but in vivo delivery methods for CRISPR components are still under preclinical surveillance.
Clustered randomly interspaced short palindromic repeats (CRISPRs) and its associated endonuclease protein, i.e., Cas9, have been discovered as an immune system in bacteria and archaea; nevertheless, they are now being adopted as mainstream biotechnological/molecular scissors that can modulate ample genetic and nongenetic diseases via insertion/deletion, epigenome editing, messenger RNA editing, CRISPR interference, etc. Many Food and Drug Administration-approved and ongoing clinical trials on CRISPR adopt ex vivo strategies, wherein the gene editing is performed ex vivo, followed by reimplantation to the patients. However, the in vivo delivery of the CRISPR components is still under preclinical surveillance. This review has summarized the nonviral nanodelivery strategies for gene editing using CRISPR/Cas9 and its recent advancements, strategic points of view, challenges, and future aspects for tissue-specific in vivo delivery of CRISPR/Cas9 components using nanomaterials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available